Ghent University Academic Bibliography

Advanced

Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study

Ruth Ladenstein, Domonique Valteau-Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Genevieve Laureys UGent, Josef Malis, Vassilios Papadakis, Ana Lacerda, Ellen Ruud, et al. (2010) JOURNAL OF CLINICAL ONCOLOGY. 28(21). p.3516-3524
abstract
Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High- Risk Neuroblastoma- 1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 mu g/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P = .001), severe leucopenia (P = .001), neutropenia (P = .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
ACUTE LYMPHOBLASTIC-LEUKEMIA, RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY, NON-HODGKINS-LYMPHOMA, FEBRILE NEUTROPENIA, STAGE-4 NEUROBLASTOMA, ONCOLOGY-GROUP, METASTATIC NEUROBLASTOMA, DAILY FILGRASTIM, CHILDREN OLDER, GROWTH-FACTORS
journal title
JOURNAL OF CLINICAL ONCOLOGY
J. Clin. Oncol.
volume
28
issue
21
pages
3516 - 3524
Web of Science type
Article
Web of Science id
000280003700018
JCR category
ONCOLOGY
JCR impact factor
18.97 (2010)
JCR rank
4/181 (2010)
JCR quartile
1 (2010)
ISSN
0732-183X
DOI
10.1200/JCO.2009.27.3524
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1143723
handle
http://hdl.handle.net/1854/LU-1143723
date created
2011-02-09 14:06:04
date last changed
2016-12-19 15:43:52
@article{1143723,
  abstract     = {Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High- Risk Neuroblastoma- 1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim).
Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 mu g/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled.
Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P = .001), severe leucopenia (P = .001), neutropenia (P = .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50\% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest.
Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.},
  author       = {Ladenstein, Ruth and Valteau-Couanet, Domonique and Brock, Penelope and Yaniv, Isaac and Castel, Victoria and Laureys, Genevieve and Malis, Josef and Papadakis, Vassilios and Lacerda, Ana and Ruud, Ellen and Kogner, Per and Garami, Miklos and Balwierz, Walentyna and Schroeder, Henrik and Beck-Popovic, Maja and Schreier, Guenter and Machin, David and Potschger, Ulrike and Pearson, Andrew},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  keyword      = {ACUTE LYMPHOBLASTIC-LEUKEMIA,RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY,NON-HODGKINS-LYMPHOMA,FEBRILE NEUTROPENIA,STAGE-4 NEUROBLASTOMA,ONCOLOGY-GROUP,METASTATIC NEUROBLASTOMA,DAILY FILGRASTIM,CHILDREN OLDER,GROWTH-FACTORS},
  language     = {eng},
  number       = {21},
  pages        = {3516--3524},
  title        = {Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study},
  url          = {http://dx.doi.org/10.1200/JCO.2009.27.3524},
  volume       = {28},
  year         = {2010},
}

Chicago
Ladenstein, Ruth, Domonique Valteau-Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Genevieve Laureys, Josef Malis, et al. 2010. “Randomized Trial of Prophylactic Granulocyte Colony-stimulating Factor During Rapid COJEC Induction in Pediatric Patients with High-risk Neuroblastoma: The European HR-NBL1/SIOPEN Study.” Journal of Clinical Oncology 28 (21): 3516–3524.
APA
Ladenstein, R., Valteau-Couanet, D., Brock, P., Yaniv, I., Castel, V., Laureys, G., Malis, J., et al. (2010). Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study. JOURNAL OF CLINICAL ONCOLOGY, 28(21), 3516–3524.
Vancouver
1.
Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study. JOURNAL OF CLINICAL ONCOLOGY. 2010;28(21):3516–24.
MLA
Ladenstein, Ruth, Domonique Valteau-Couanet, Penelope Brock, et al. “Randomized Trial of Prophylactic Granulocyte Colony-stimulating Factor During Rapid COJEC Induction in Pediatric Patients with High-risk Neuroblastoma: The European HR-NBL1/SIOPEN Study.” JOURNAL OF CLINICAL ONCOLOGY 28.21 (2010): 3516–3524. Print.